Table of Contents
Executive Summary
1 Industry Overview of Myelodysplastic Syndrome (MDS) Treatment
1.1 Definition of Myelodysplastic Syndrome (MDS) Treatment
1.2 Myelodysplastic Syndrome (MDS) Treatment Segment by Type
1.2.1 Global Myelodysplastic Syndrome (MDS) Treatment Production Growth Rate Comparison by Types (2014-2025)
1.2.2 Azacitidine
1.2.3 Lenalidomide
1.2.4 Decitabine
1.2.5 Deferasirox
1.3 Myelodysplastic Syndrome (MDS) Treatment Segment by Applications
1.3.1 Global Myelodysplastic Syndrome (MDS) Treatment Consumption Comparison by Applications (2014-2025)
1.3.2 Refractory cytopenia with unilineage dysplasia
1.3.3 Refractory anemia with ringed sideroblasts
1.3.4 Others
1.4 Global Myelodysplastic Syndrome (MDS) Treatment Overall Market
1.4.1 Global Myelodysplastic Syndrome (MDS) Treatment Revenue (2014-2025)
1.4.2 Global Myelodysplastic Syndrome (MDS) Treatment Production (2014-2025)
1.4.3 North America Myelodysplastic Syndrome (MDS) Treatment Status and Prospect (2014-2025)
1.4.4 Europe Myelodysplastic Syndrome (MDS) Treatment Status and Prospect (2014-2025)
1.4.5 China Myelodysplastic Syndrome (MDS) Treatment Status and Prospect (2014-2025)
1.4.6 Japan Myelodysplastic Syndrome (MDS) Treatment Status and Prospect (2014-2025)
1.4.7 Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Status and Prospect (2014-2025)
1.4.8 India Myelodysplastic Syndrome (MDS) Treatment Status and Prospect (2014-2025)
2 Manufacturing Cost Structure Analysis
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Myelodysplastic Syndrome (MDS) Treatment
2.3 Manufacturing Process Analysis of Myelodysplastic Syndrome (MDS) Treatment
2.4 Industry Chain Structure of Myelodysplastic Syndrome (MDS) Treatment
3 Development and Manufacturing Plants Analysis of Myelodysplastic Syndrome (MDS) Treatment
3.1 Capacity and Commercial Production Date
3.2 Global Myelodysplastic Syndrome (MDS) Treatment Manufacturing Plants Distribution
3.3 Major Manufacturers Technology Source and Market Position of Myelodysplastic Syndrome (MDS) Treatment
3.4 Recent Development and Expansion Plans
4 Key Figures of Major Manufacturers
4.1 Myelodysplastic Syndrome (MDS) Treatment Production and Capacity Analysis
4.2 Myelodysplastic Syndrome (MDS) Treatment Revenue Analysis
4.3 Myelodysplastic Syndrome (MDS) Treatment Price Analysis
4.4 Market Concentration Degree
5 Myelodysplastic Syndrome (MDS) Treatment Regional Market Analysis
5.1 Myelodysplastic Syndrome (MDS) Treatment Production by Regions
5.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Production by Regions
5.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Regions
5.2 Myelodysplastic Syndrome (MDS) Treatment Consumption by Regions
5.3 North America Myelodysplastic Syndrome (MDS) Treatment Market Analysis
5.3.1 North America Myelodysplastic Syndrome (MDS) Treatment Production
5.3.2 North America Myelodysplastic Syndrome (MDS) Treatment Revenue
5.3.3 Key Manufacturers in North America
5.3.4 North America Myelodysplastic Syndrome (MDS) Treatment Import and Export
5.4 Europe Myelodysplastic Syndrome (MDS) Treatment Market Analysis
5.4.1 Europe Myelodysplastic Syndrome (MDS) Treatment Production
5.4.2 Europe Myelodysplastic Syndrome (MDS) Treatment Revenue
5.4.3 Key Manufacturers in Europe
5.4.4 Europe Myelodysplastic Syndrome (MDS) Treatment Import and Export
5.5 China Myelodysplastic Syndrome (MDS) Treatment Market Analysis
5.5.1 China Myelodysplastic Syndrome (MDS) Treatment Production
5.5.2 China Myelodysplastic Syndrome (MDS) Treatment Revenue
5.5.3 Key Manufacturers in China
5.5.4 China Myelodysplastic Syndrome (MDS) Treatment Import and Export
5.6 Japan Myelodysplastic Syndrome (MDS) Treatment Market Analysis
5.6.1 Japan Myelodysplastic Syndrome (MDS) Treatment Production
5.6.2 Japan Myelodysplastic Syndrome (MDS) Treatment Revenue
5.6.3 Key Manufacturers in Japan
5.6.4 Japan Myelodysplastic Syndrome (MDS) Treatment Import and Export
5.7 Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Market Analysis
5.7.1 Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Production
5.7.2 Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Revenue
5.7.3 Key Manufacturers in Southeast Asia
5.7.4 Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Import and Export
5.8 India Myelodysplastic Syndrome (MDS) Treatment Market Analysis
5.8.1 India Myelodysplastic Syndrome (MDS) Treatment Production
5.8.2 India Myelodysplastic Syndrome (MDS) Treatment Revenue
5.8.3 Key Manufacturers in India
5.8.4 India Myelodysplastic Syndrome (MDS) Treatment Import and Export
6 Myelodysplastic Syndrome (MDS) Treatment Segment Market Analysis (by Type)
6.1 Global Myelodysplastic Syndrome (MDS) Treatment Production by Type
6.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Type
6.3 Myelodysplastic Syndrome (MDS) Treatment Price by Type
7 Myelodysplastic Syndrome (MDS) Treatment Segment Market Analysis (by Application)
7.1 Global Myelodysplastic Syndrome (MDS) Treatment Consumption by Application
7.2 Global Myelodysplastic Syndrome (MDS) Treatment Consumption Market Share by Application (2014-2019)
8 Myelodysplastic Syndrome (MDS) Treatment Major Manufacturers Analysis
8.1 Novartis AG
8.1.1 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
8.1.2 Novartis AG Product Introduction, Application and Specification
8.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.1.4 Main Business and Markets Served
8.2 Celgene Corporation
8.2.1 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
8.2.2 Celgene Corporation Product Introduction, Application and Specification
8.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.2.4 Main Business and Markets Served
8.3 Otsuka Pharmaceutical Co., Ltd
8.3.1 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
8.3.2 Otsuka Pharmaceutical Co., Ltd Product Introduction, Application and Specification
8.3.3 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.3.4 Main Business and Markets Served
8.4 Sandoz Inc
8.4.1 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
8.4.2 Sandoz Inc Product Introduction, Application and Specification
8.4.3 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.4.4 Main Business and Markets Served
8.5 Dr Reddys Laboratories Limited
8.5.1 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
8.5.2 Dr Reddys Laboratories Limited Product Introduction, Application and Specification
8.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.5.4 Main Business and Markets Served
8.6 Pharmascience Inc
8.6.1 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
8.6.2 Pharmascience Inc Product Introduction, Application and Specification
8.6.3 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.6.4 Main Business and Markets Served
8.7 Accord Healthcare Ltd
8.7.1 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
8.7.2 Accord Healthcare Ltd Product Introduction, Application and Specification
8.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.7.4 Main Business and Markets Served
8.8 Mylan N.V.
8.8.1 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
8.8.2 Mylan N.V. Product Introduction, Application and Specification
8.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.8.4 Main Business and Markets Served
9 Development Trend of Analysis of Myelodysplastic Syndrome (MDS) Treatment Market
9.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Trend Analysis
9.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Size (Volume and Value) Forecast 2019-2025
9.2 Myelodysplastic Syndrome (MDS) Treatment Regional Market Trend
9.2.1 North America Myelodysplastic Syndrome (MDS) Treatment Forecast 2019-2025
9.2.2 Europe Myelodysplastic Syndrome (MDS) Treatment Forecast 2019-2025
9.2.3 China Myelodysplastic Syndrome (MDS) Treatment Forecast 2019-2025
9.2.4 Japan Myelodysplastic Syndrome (MDS) Treatment Forecast 2019-2025
9.2.5 Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Forecast 2019-2025
9.2.6 India Myelodysplastic Syndrome (MDS) Treatment Forecast 2019-2025
9.3 Myelodysplastic Syndrome (MDS) Treatment Market Trend (Product Type)
9.4 Myelodysplastic Syndrome (MDS) Treatment Market Trend (Application)
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.3 Myelodysplastic Syndrome (MDS) Treatment Customers
11 Market Dynamics
11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors
12 Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer
【掲載企業】
Novartis AG、Celgene Corporation、Otsuka Pharmaceutical Co., Ltd、Sandoz Inc、Dr Reddys Laboratories Limited、Pharmascience Inc、Accord Healthcare Ltd、Mylan N.V.